The invention relates to a variant of p14 (ARF) tumor suppressor which exhibits resistance to proteolytic degradation. The invention also relates to a nucleic acid molecule which codes for this variant. Also disclosed are peptides preventing proteolytic degradation of p14 (ARF) by binding to p14 (ARF) and nucleic acid molecules which code for said peptide. Vectors containing said nucleic acid molecules are further disclosed whereby said vectors are suitable for use in the gene therapy of tumors. Medicaments are also disclosed containing the aforementioned nucleic acid molecules or vectors or proteins or peptides coded thereby for the treatment of leukemia.
展开▼